<DOC>
	<DOCNO>NCT01771471</DOCNO>
	<brief_summary>This clinical study collect safety preliminary efficiency information use NuQu chondrocytes ( cartilage cell ) deliver center lumbar spinal disc treat low back pain .</brief_summary>
	<brief_title>A Study Comparing Safety Effectiveness Cartilage Cell Injected Into Lumbar Disc Compared Placebo</brief_title>
	<detailed_description>This Phase II clinical study collect additional safety data preliminary efficiency juvenile chondrocytes , deliver fibrin carrier ( NuQu® ) nucleus lumbar intervertebral disc treatment discogenic pain . This accomplish double blind , placebo-controlled study clinically meaningful endpoint include validate , subject report outcomes pain disability , health relate quality life subject satisfaction treatment .</detailed_description>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Subject able provide inform consent must sign Institutional Review Board approve Informed Consent Form ; Is least 21 year age ; Have central low back pain aggravate movement postural change ( standing/sitting ) ; Have back pain least 6 month , fail conservative management One Grade III IV ( Pfirrmann Scale ) degenerate lumbar disc ; Current disc extrusion level lumbar spine ; disc bulge protrusion level lumbar spine result nerve root compression ; Severe disc narrow ( equal 50 % loss disc height target level ) ; Type II III Modic change level ; Type I Modic change level targeted level ; Type I Modic change treat level maximum height change 25 % vertebral body height ; Osteoporotic compression fracture vertebral level ; Lumbar Scheurmann 's disease ; Antero retrolisthesis ≥ 3mm level ; Currently experience chronic pain generate source , ( judgment investigator ) may interfere evaluation back pain , disability ; Infection plan treatment site , history systemic local infection , ( investigator 's judgment ) may compromise subject participation and/or safety ; Currently diagnose immunedeficiency , investigator 's opinion may compromise subject participation and/or safety ; Receiving immunesuppressant therapy short term steroid preparation ; BMI≥40 ; Diagnosed comorbid condition include : abnormal bleeding , AIDS , diabetes , hepatic renal disease , cardiopulmonary disorder COPD , MI CHF ; active malignancy history malignancy , diseases bone metabolism , investigator 's opinion may compromise subject participation and/or safety ; Has history alcoholism , medication intravenous drug abuse , psychosis , prisoner , personality disorder ( ) , poor motivation , emotional intellectual issue would likely make subject unreliable study , 3 Waddell Signs nonorganic Behavior combination variable Investigator 's judgment exclude potential subject ; Has pending litigation health care professional , except require insurer condition coverage , personal injury compensation litigation claim ; Has active pending worker ' compensation claim ; Has contraindication MRI .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>back pain</keyword>
	<keyword>intervertebral disc</keyword>
	<keyword>lumbar spine</keyword>
</DOC>